These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8837524)

  • 1. A pharmacodynamic model for the action of the antibiotic imipenem on Pseudomonas aeruginosa populations in vitro.
    Berg PH; Voit EO; White RL
    Bull Math Biol; 1996 Sep; 58(5):923-38. PubMed ID: 8837524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to imipenem in Pseudomonas aeruginosa.
    King A; Shannon K; Phillips I
    J Antimicrob Chemother; 1995 Dec; 36(6):1037-41. PubMed ID: 8821603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H
    J Antimicrob Chemother; 1996 Aug; 38(2):287-91. PubMed ID: 8877544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program.
    Turner PJ
    Diagn Microbiol Infect Dis; 2006 Nov; 56(3):341-4. PubMed ID: 17049798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa.
    Kuti JL; Florea NR; Nightingale CH; Nicolau DP
    Pharmacotherapy; 2004 Jan; 24(1):8-15. PubMed ID: 14740783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbapenem-induced resistance to beta-lactams in Pseudomonas aeruginosa.
    Giacometti A; Del Prete MS; Cirioni O; Izat MK; Balducci M; Cesarini AM; Scalise G
    J Chemother; 1995 Nov; 7 Suppl 4():76-7. PubMed ID: 8904115
    [No Abstract]   [Full Text] [Related]  

  • 7. The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
    Erdem I; Kaynar-Tascioglu J; Kaya B; Goktas P
    Int J Antimicrob Agents; 2002 Nov; 20(5):384-6. PubMed ID: 12431875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imipenem and meropenem induced resistance to beta-lactam antibiotics in Pseudomonas aeruginosa.
    Giacometti A; Siquini FM; Cirioni O; Petroni S; Scalise G
    Eur J Clin Microbiol Infect Dis; 1994 Apr; 13(4):315-8. PubMed ID: 8070438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
    Hu YF; Liu CP; Wang NY; Shih SC
    BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa.
    Tessier F; Quentin C
    Eur J Clin Microbiol Infect Dis; 1997 Feb; 16(2):159-62. PubMed ID: 9105845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imipenem: morphological changes and lethal effects on Pseudomonas aeruginosa.
    Carlone NA; Ferrero M; Cuffini AM; Cavallo R
    Drugs Exp Clin Res; 1987; 13(10):623-9. PubMed ID: 3123190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outer membrane proteins profiles of Pseudomonas aeruginosa after the post-antibiotic effect of imipenem.
    Hostacká A; Karelová E
    Microbios; 1997; 90(362):45-50. PubMed ID: 9301070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of resistance to imipenem among nosocomial isolates of Pseudomonas aeruginosa.
    Başustaoğlu AC; Gün H; Saraçli MA; Baysallar M; Haznedaroğlu T
    Eur J Clin Microbiol Infect Dis; 1995 May; 14(5):469-70. PubMed ID: 7556242
    [No Abstract]   [Full Text] [Related]  

  • 14. Detection of outer membrane porin protein, an imipenem influx channel, in Pseudomonas aeruginosa clinical isolates.
    Naenna P; Noisumdaeng P; Pongpech P; Tribuddharat C
    Southeast Asian J Trop Med Public Health; 2010 May; 41(3):614-24. PubMed ID: 20578550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic effects of subinhibitory concentrations of imipenem on Pseudomonas aeruginosa in an in vitro dynamic model.
    Maggiolo F; Taras A; Frontespezi S; Legnani MC; Silanos MA; Pravettoni G; Suter F
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1416-8. PubMed ID: 8092847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa.
    Hagihara M; Kuti JL; Nicolau DP
    Diagn Microbiol Infect Dis; 2012 Mar; 72(3):258-62. PubMed ID: 22209563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postantibiotic effect of imipenem, alone and in combination with amikacin, on Pseudomonas aeruginosa.
    Gerçeker AA; Otük G
    Chemotherapy; 1995; 41(6):433-6. PubMed ID: 8529433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
    Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of superinhibitory levels of imipenem and amikacin singly or in combination on Pseudomonas aeruginosa].
    Hostacká A
    Epidemiol Mikrobiol Imunol; 1997 Dec; 46(4):155-7. PubMed ID: 9471306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa.
    Shibata K; Adachi Y; Kato E; Nagano R; Fuse A; Hashizume T; Ohtake N; Okamoto O; Nakagawa S
    J Antibiot (Tokyo); 1997 Feb; 50(2):135-8. PubMed ID: 9099222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.